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To the Editor,
Purine nucleoside phosphorylase (PNP) deficiency is a rare
metabolic disorder leading to combined immunodeficiency
(CID) and neurological deficits such as developmental delay,
ataxia, and motor impairment. PNP is highly expressed in red
blood cells (RBC) and phosphorolyzes (deoxy)-inosine and
(deoxy)-guanosine to (deoxy)-guanine and hypoxanthine.
Due to the enzymatic block, PNP-deficient patients display
elevated concentrations of purine (deoxy-)nucleosides which
have lympho- and neurotoxic effects. For example, dGTP
which accumulates in mitochondria inhibits the synthesis of
mitochondrial DNA leading to apoptosis and contributes to
the neurological deficits [1]. The metabolic block caused by
PNP deficiency prevents uric acid formation and frequently
results in hypouricemia [2]. PNP deficiency can be treated
with HSCT leading to correction of CID, but neurological
deficits often remain or progress. A pioneering proof-of-
concept work in the 1980s has shown that erythrocyte trans-
fusions improve metabolic and immunologic functions [3, 4].
With the implementation of TREC-based newborn screening
and the possibility to screen for PNP deficiency by tandem
mass spectrometry, which would be more sensitive, there is a
growing need for managing asymptomatic newborn PNP
patients (P), not only curing CID but also preventing neuro-
logical deficits [5].
We report a series of three neonates/infants who had re-
ceived a genetic diagnosis of PNP deficiency prenatally (P1
and P2, siblings) or early in life (P3) because of familial index
cases (Tab.S1). They all had sequential therapy with immedi-
ate and ongoing erythrocyte transfusions (ET) followed by
HSCT (Fig. 1). Before the initial erythrocyte exchange trans-
fusions (EET), PNP RBC enzyme activity was decreased to
4.8 ± 3.3 μmol/min/g hemoglobin (reference 60–100) and
dried blood spot purine metabolites were elevated (e.g., gua-
nosine 12.3 ± 5.5 μmol/l; reference <1.1, Fig. 1, Tab.S3–S5).
Uric acid was only reduced in P3 (0.2 mg/dl uric acid on day 6
of life), while it was normal to slightly elevated in P1 and P2
(Fig.S2). While postnatal clinical examination and cerebral
ultrasound (patients 1 and 2) showed no neurological abnor-
malities, there were varying degrees of immune cell reduction
(Tab.S2). Initial EET was performed immediately after birth
in P1 and P2, and on day 23 of life in P3. These erythrocyte
exchange transfusions on day 1 of life led to an increase in
PNP enzyme activity to 50 (P1) and 21 (P2) μmol/min/g he-
moglobin (at d2 of life) and a normalization of purine metab-
olites (as exemplified by guanosine 0.5 ± 0.1 μmol/l) (Fig. 1,
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Tab.S4–S6). Thereafter, P1–P3 received regular ET/EET fol-
lowing individualized schemes that were guided by purine
metabolites (Fig. 1, Tab.S4–S6). P1 received five additional
ET every 11 ± 10 days with a volume of 15 ± 9 ml/kg without
prior phlebotomy due to anemia caused by concomitant sickle
cell disease (Fig. 1a and Tab.S4). P2 received nine additional
EET every 12 ± 5 days with a volume of 14 ± 2 ml/kg preced-
ed by 6 phlebotomies of 10 ± 4ml/kg (Fig. 1b and Tab.S5). P3
received 2 additional ET every 24 ± 6 days with a volume of
24 ml/kg (day 43) and an unclear ET volume (day 71) (Fig. 1c
and Tab.S6). After the initial EET, P1 and P2 had thrombo-
cytopenia (41G/l and 28G/l) without bleeding signs and both
received thrombocyte transfusions once. P1 had transient par-
tial respiratory insufficiency with oxygen dependency via na-
sal cannula and P2 had mild fluid overload and received two
doses of furosemide. P3 had mild thrombocytopenia after the
first (108G/l) and after the second ET (138G/l). No further
adverse events related to EET/ET were observed.
To achieve definitive cure of PNP deficiency, P1–P3
underwent allogeneic HSCT after busulfan/fludarabine/
alemtuzumab-based myeloablative conditioning from mis-
matched family or matched unrelated donors at the age of 64
to 117 days, respectively (Tab.S1). HSCT of P1 was compli-
cated by veno-occlusive disease that responded to defibrotide
and by secondary graft failure (Fig. 1, Tab.S1 and S4). While
peripheral blood donor chimerism was declining (72% on day
+196), toxic purine metabolites increased in peripheral blood
and cerebrospinal fluid. At this time point, P1 had no signs of
CID, but neurological development slowed down. No ETs
were performed between the diagnosis of secondary graft fail-
ure and second HSCT. Patient 1 was uneventfully re-
transplanted at the age of 19months from the same donor with
an alternative myeloablative regimen and stem cell source
(Tab.S1). P2 experienced acute graft-versus-host disease
(GVHD) °III that responded to immunosuppressive therapy.
The transplantation of P3 was uneventful without major com-
plications. With a follow-up of 42, 32, and 37 months, respec-
tively, all patients are alive and well with complete immune
reconstitution and no chronic GVHD.
P1–P3 have successively reached developmental mile-
stones at the follow-up visits; however, they have global de-
velopmental delay of varying degrees (Tab. S3). P1 and P3
were able to partially catch-up cognitive development while
P2 has shown slower progress. Analyzing guanosine levels
over time (Fig. 1), it is hard to determine different AUCs.
Moreover, a variety of additional factors—e.g., different ge-
notypes (P1/2 versus P3), intrauterine exposure to toxic purine
metabolites [6], 2nd HSCT in P1, prolonged glucocorticoid
use, and failure to thrive due to acute GVHD in P2—
distinguish P1–P3 and may influence neurological develop-
ment. Especially, the timing of exposure to substantially ele-
vated neurotoxic metabolites might influence motor develop-
ment. P3 who started ET/EETs at the age of 23 days and thus
spent most of her newborn period with highly toxic levels
cannot walk independently at the age of 3 years, while P1
and P2 are mobile on their own. Motor development, howev-
er, is most impaired in P1–P3 and P3 is doing better in other
areas of the testing as compared to P1 and P2. Neuroimaging
of P3 reveals global brain atrophy (Fig. S1) at the age of
28 months while there is none for P1 and P2.
Observations in single PNP patients suggest that neurolog-




Fig. 1 Clinical course of patients 1 (a), 2 (b), and 3 (c) indicating the time
points of erythrocyte transfusions (EET/ETs) and HSCT, corresponding
guanosine levels from dried blood spots (black, dots), and whole-blood
chimerism after HSCT (gray, dashed-dotted line, triangles). Only ETs
prior to HSCT, not those during aplasia after chemotherapy, are
displayed. The upper reference value for guanosine (1.1 μmol/l) is
marked with a black dashed line. CSF, cerebrospinal fluid
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progress especially after late HSCT [7, 8]. Clearly, larger
HSCT series with long-term outcome data are lacking.
Moreover, in the preexisting literature, no clear genotype-
phenotype correlations were shown for the neurological out-
come and the development of the children is also influenced
by the acquired infections [9]. Thus, it is impossible to gauge
the neurological outcome in a single patient and it is difficult
to evaluate the effect of therapeutic interventions. Untreated
murine PNP deficiency causes comparable neurological defi-
cits that can be prevented by ERT [10]. Transient treatment
with ET to provide PNP enzyme has established the proof of
principle that this can lead to short-lasting biochemical and
immunological improvement34. We here demonstrate in a
case series of neonates/infants with PNP deficiency that this
approach is safe as an upfront strategy followed by early de-
finitive HSCT in pre-symptomatic patients. Initial EET should
be performed under tight supervision of an experienced team
in a distinguished expert center once the newborn is stable,
and special attention should be paid to hypocalcemia, hypo-
magnesemia, and thrombocytopenia [11, 12]. Detection of
purine metabolites with tandem mass spectrometry allows to
guide ET regimens and to optimize the amount of red blood
cell transfusions, thereby maintaining purine metabolites in
the lower range and avoiding unnecessary transfusion-
induced iron overload. The uric acid levels in our three pa-
tients were not corresponding well enough to purine metabo-
lite levels and could not be used for transfusion guidance
(Fig.S2), therefore justifying the more elaborate application
of tandem mass spectrometry to directly measure purine me-
tabolites. We show that this approach results in correction of
purine metabolites and stabilizes the immunological pheno-
types (Tab.S7–S8). We hypothesize that improved neuropro-
tection could be reached by immediate (EET), consecutive ET
and long-lasting cross-detoxification (HSCT), even though
significant long-term neurological benefit remains to be deter-
mined. We propose that the possible neurological benefit out-
weighs the possible complications of EET/ET that could be
applied as a bridge to HSCT at the earliest possible time point.
We envision that intrauterine ETs in PNP-deficient fetuses
might further improve their neurocognitive development.
In non-malignant immunological and metabolic disorders,
the degree of donor chimerism required for cure varies con-
siderably across diseases and the particular cell lineages [13].
In PNP deficiency, the central nervous system requirement for
PNP enzyme activity can only be targeted indirectly by
HSCT. Thus, the conditioning regimen should allow for donor
monocytemigration to the central nervous system and ensuing
trans-differentiation into microglia-like cells. In animal
models, this could best be achieved by busulfan-containing
conditioning which we chose for P1–P3. Consequently, high
donor myeloid chimerism should be obtained and properly
monitored. While RBC represent the main source of PNP,
their chimerism cannot be assessed easily in peripheral blood
with standard genetic techniques. We show that monitoring
purine metabolites can detect rising metabolites as a conse-
quence of incomplete RBC and myeloid chimerism and pro-
pose it as a technique to monitor ADA and PNP deficiency
after HSCT and gene therapy.
In summary, therapy of PNP deficiency with upfront en-
zyme replacement via EET/ET combined with definitive
HSCT leads to immediate and permanent correction of meta-
bolic and immunological phenotypes, while long-term neuro-
logical benefit remains to be determined.Monitoring of purine
metabolites by tandem mass spectrometry is feasible for
governing individual ET regimens and for detecting early
graft failure especially of the erythroid lineage.
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